Biosimilars: the need, the challenge, the future: the FDA perspective - Wikidata - awgldk - TriplyDB

Biosimilars: the need, the challenge, the future: the FDA perspective

Biosimilars: the need, the challenge, the future: the FDA perspective

http://www.wikidata.org/entity/Q28242669

about

Biosimilars: potential implications for clinicians An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions

P2860

Q26744332-FDCFEF44-CC6D-46FC-8A39-0487AC24093F Q35762997-4F7720B0-5363-417E-ADFB-029445938379 Q35975965-7D711AD3-E3FD-4248-88F4-4F617503513D Q38432853-881EE832-30D8-4A58-AD2A-5991BD6ACD82 Q38977625-40D24D5E-5975-4F78-8D98-9553C6D9672B Q39066090-802D5120-C6BC-4783-B905-3C09906FAFA1 Q56835543-7B42C719-727E-40A0-9C62-FDCC4C246F59

P2860

Biosimilars: the need, the challenge, the future: the FDA perspective

http://www.wikidata.org/entity/Q28242669

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Biosimilars: the need, the challenge, the future: the FDA perspective

@ast

Biosimilars: the need, the challenge, the future: the FDA perspective

@en

Biosimilars: the need, the challenge, the future: the FDA perspective

@nl

type

label

Biosimilars: the need, the challenge, the future: the FDA perspective

@ast

Biosimilars: the need, the challenge, the future: the FDA perspective

@en

Biosimilars: the need, the challenge, the future: the FDA perspective

@nl

prefLabel

Biosimilars: the need, the challenge, the future: the FDA perspective

@ast

Biosimilars: the need, the challenge, the future: the FDA perspective

@en

Biosimilars: the need, the challenge, the future: the FDA perspective

@nl

P1433

Q28242669-51EBD5A2-8AF0-4B1E-B3D0-1CBE948DA097

P1476

Q28242669-6DFC6BF8-B671-4193-A850-FA07D20E0CCA

P2093

Q28242669-369F43ED-107B-4DB0-AFC4-94A160C6E514

Q28242669-5138020B-B021-4E1F-87CB-04A289EEC196

Q28242669-D0069456-F7F3-4040-A8AD-9775C09942F9

P2860

Q28242669-02DC966A-20B1-43CE-B16C-D3FE54149725

Q28242669-13A1BD51-3A95-489A-BB5E-9251F382A237

Q28242669-2372BE67-10BC-4549-B236-44993F66EA37

Q28242669-65510942-0065-4643-A339-4801F0EFFFF1

Q28242669-6BFF4B80-B676-4BE3-840B-5A8307000503

Q28242669-A7BE767A-4762-4AC6-B1D0-04971E73A534

Q28242669-C9F21A9D-CE7E-4C26-A5AB-B4F088850B63

Q28242669-DA4C564E-C209-43F8-96A8-1451696C4E17

Q28242669-EAA70C0F-A8C4-40D9-9686-6DFA4C3EA77A

P2888

Q28242669-7C4B91DF-D9CC-46D2-8A66-FAA0EA11CDAD

P304

Q28242669-4196B16D-7FD3-4382-9E53-53AD166BD411

P31

Q28242669-89DFBF97-B2EF-4EEC-AB58-6317F3319642

P3181

Q28242669-F5F7E466-41F4-48B8-8B14-CC530A3D97AA

P356

Q28242669-2441C4EC-067E-4EB2-A3A8-CA2574572E14

P407

Q28242669-ED8640BD-6773-45E2-BDD5-D096B077BBC0

P433

Q28242669-55F69DF7-226F-4CB9-907F-13171CE58043

P478

Q28242669-98180141-EA29-4122-918F-D6D5835025D6

P577

Q28242669-4503557B-522B-43C0-8ECB-2DC09FAA0B75

P6179

Q28242669-578E25D7-CE7D-48BE-A089-B7BFE8866C63

P698

Q28242669-A65BBFD3-95BC-4DEC-9F5C-0C781352597F

P3181

P356

P1433

The American Journal of Gastroenterology

P1476

Biosimilars: the need, the challenge, the future: the FDA perspective

@en

P2093

Eli D Ehrenpreis

http://www.w3.org/2001/XMLSchema#string

Michael S Epstein

http://www.w3.org/2001/XMLSchema#string

Prasad M Kulkarni

http://www.w3.org/2001/XMLSchema#string

P2860

Biosimilars: company strategies to capture value from the biologics market

Risk management of biosimilars in oncology: each medicine is a work in progress.

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.

Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.

Biosimilar insulins.

Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.

Current status of biosimilar growth hormone.

Biosimilar therapeutics-what do we need to consider?

How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.

P2888

P304

1856-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

704323

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/AJG.2014.151

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038609913

http://www.w3.org/2001/XMLSchema#string

P698

24957160

http://www.w3.org/2001/XMLSchema#string